Literature DB >> 21245154

HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers.

Peter W Hunt1, Hiroyu Hatano, Elizabeth Sinclair, Tzong-Hae Lee, Michael P Busch, Jeffrey N Martin, Joseph M McCune, Steven G Deeks.   

Abstract

BACKGROUND: Human immunodeficiency virus (HIV)--infected individuals maintaining plasma HIV RNA levels <75 copies/mL in the absence of therapy ("HIV controllers") often maintain high HIV-specific T cell responses, which likely contribute to the control of viral replication. Despite robust immune responses, these individuals never eradicate HIV infection. We hypothesized that HIV-specific CD4(+) T cells might serve as target cells for HIV, contributing to viral persistence in this setting.
METHODS: We measured frequencies of activated (CD38(+) HLA-DR(+)) and HIV Gag-specific CD4(+) and CD8(+) T cells and plasma- and cell-associated levels of HIV RNA and DNA in a cohort of 38 HIV controllers.
RESULTS: Although there was no evidence of a relationship between the extent of low-level viremia and the frequency of either activated or HIV-specific CD4(+) T cells, controllers with higher HIV-specific CD4(+) T cell frequencies had higher cell-associated HIV DNA levels (ρ = 0.53; P = .019). Higher activated CD4+ T cell frequencies were also associated with higher levels of cell-associated DNA (P = .027) and RNA (P = .0096). However, there was no evidence of a relationship between cell-associated HIV RNA or DNA levels and HIV-specific CD8(+) T cell frequencies.
CONCLUSIONS: These data support a model in which strong HIV-specific CD4(+) T cell responses in HIV controllers, while contributing to a potent adaptive immune response, may also contribute to viral persistence, preventing the natural eradication of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245154      PMCID: PMC3060894          DOI: 10.1093/cid/ciq202

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  42 in total

1.  Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02).

Authors:  Sophie Limou; Sigrid Le Clerc; Cédric Coulonges; Wassila Carpentier; Christian Dina; Olivier Delaneau; Taoufik Labib; Lieng Taing; Rob Sladek; Christiane Deveau; Rojo Ratsimandresy; Matthieu Montes; Jean-Louis Spadoni; Jean-Daniel Lelièvre; Yves Lévy; Amu Therwath; François Schächter; Fumihiko Matsuda; Ivo Gut; Philippe Froguel; Jean-François Delfraissy; Serge Hercberg; Jean-François Zagury
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

2.  Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection.

Authors:  Daniëlle van Manen; Neeltje A Kootstra; Brigitte Boeser-Nunnink; Muna Am Handulle; Angélique B van't Wout; Hanneke Schuitemaker
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

3.  Glycerol monolaurate prevents mucosal SIV transmission.

Authors:  Qingsheng Li; Jacob D Estes; Patrick M Schlievert; Lijie Duan; Amanda J Brosnahan; Peter J Southern; Cavan S Reilly; Marnie L Peterson; Nancy Schultz-Darken; Kevin G Brunner; Karla R Nephew; Stefan Pambuccian; Jeffrey D Lifson; John V Carlis; Ashley T Haase
Journal:  Nature       Date:  2009-03-04       Impact factor: 49.962

4.  Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B*57+ elite suppressors.

Authors:  Justin R Bailey; Timothy P Brennan; Karen A O'Connell; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

5.  Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.

Authors:  Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Joan Dunn-Williams; Peter W Hunt; Rebecca Hoh; Susan L Stramer; Jeffrey M Linnen; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Steven G Deeks
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

6.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

7.  HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition.

Authors:  Toshiyuki Miura; Mark A Brockman; Arne Schneidewind; Michael Lobritz; Florencia Pereyra; Almas Rathod; Brian L Block; Zabrina L Brumme; Chanson J Brumme; Brett Baker; Alissa C Rothchild; Bin Li; Alicja Trocha; Emily Cutrell; Nicole Frahm; Christian Brander; Ildiko Toth; Eric J Arts; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-12-30       Impact factor: 5.103

8.  Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control.

Authors:  Stephen A Migueles; Christine M Osborne; Cassandra Royce; Alex A Compton; Rohan P Joshi; Kristin A Weeks; Julia E Rood; Amy M Berkley; Jonah B Sacha; Nancy A Cogliano-Shutta; Margaret Lloyd; Gregg Roby; Richard Kwan; Mary McLaughlin; Sara Stallings; Catherine Rehm; Marie A O'Shea; JoAnn Mican; Beverly Z Packard; Akira Komoriya; Sarah Palmer; Ann P Wiegand; Frank Maldarelli; John M Coffin; John W Mellors; Claire W Hallahan; Dean A Follman; Mark Connors
Journal:  Immunity       Date:  2008-12-08       Impact factor: 31.745

9.  Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells.

Authors:  Catherine M Card; Paul J McLaren; Charles Wachihi; Joshua Kimani; Francis A Plummer; Keith R Fowke
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

10.  Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics.

Authors:  Kara G Lassen; Michael A Lobritz; Justin R Bailey; Samantha Johnston; Sandra Nguyen; Benhur Lee; Tom Chou; Robert F Siliciano; Martin Markowitz; Eric J Arts
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

View more
  20 in total

Review 1.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

2.  Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir.

Authors:  Deborah Persaud; Katherine Luzuriaga; Carrie Ziemniak; Petronella Muresan; Thomas Greenough; Terry Fenton; Amanda Blackford; Kimberly Ferguson; Natalie Neu; Coleen K Cunningham
Journal:  AIDS       Date:  2011-11-28       Impact factor: 4.177

Review 3.  Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Authors:  Nichole R Klatt; Nicolas Chomont; Daniel C Douek; Steven G Deeks
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

4.  HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term.

Authors:  Benoît Vingert; Daniela Benati; Olivier Lambotte; Pierre de Truchis; Laurence Slama; Patricia Jeannin; Moran Galperin; Santiago Perez-Patrigeon; Faroudy Boufassa; William W Kwok; Fabrice Lemaître; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

5.  Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers.

Authors:  Alice K Asher; Glenn-Milo Santos; Jennifer Evans; Emily K Dokubo; Tzong-Hae Lee; Jeffrey N Martin; Steven G Deeks; Leslie H Tobler; Michael Busch; Peter W Hunt; Kimberly Page
Journal:  AIDS       Date:  2013-11-13       Impact factor: 4.177

6.  Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients.

Authors:  P G Stock; B Barin; H Hatano; R L Rogers; M E Roland; T-H Lee; M Busch; S G Deeks
Journal:  Am J Transplant       Date:  2014-04-03       Impact factor: 8.086

7.  P2X Antagonists Inhibit HIV-1 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1β in a Human Tonsil Explant Model.

Authors:  Alexandra Y Soare; Natasha D Durham; Ramya Gopal; Benjamin Tweel; Kevin W Hoffman; Julia A Brown; Megan O'Brien; Nina Bhardwaj; Jean K Lim; Benjamin K Chen; Talia H Swartz
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

8.  Association of low level viremia with inflammation and mortality in HIV-infected adults.

Authors:  Abigail Eastburn; Rebecca Scherzer; Andrew R Zolopa; Constance Benson; Russell Tracy; Tri Do; Peter Bacchetti; Michael Shlipak; Carl Grunfeld; Phyllis C Tien
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

9.  Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors.

Authors:  Julie C Gaardbo; Hans J Hartling; Jan Gerstoft; Susanne D Nielsen
Journal:  AIDS Res Treat       Date:  2012-05-27

Review 10.  Cell-associated HIV RNA: a dynamic biomarker of viral persistence.

Authors:  Alexander O Pasternak; Vladimir V Lukashov; Ben Berkhout
Journal:  Retrovirology       Date:  2013-04-15       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.